Exopharm Limited Banner Image

Exopharm Limited

  • Ticker EX1
    Exchange ASX More
  • Industry Biotechnology More
  • Sector Healthcare More
Exopharm Limited Logo Image
  • 11-50 Employees
  • Based in Melbourne, Australia
Exopharm Limited, a clinical-stage company, develops transformative medicines based upon extracellular vesicles (EVs) in Australia. The company's technology includes extracellular vesicle positioning system that allows specific molecules to be attached to the surface of exosomes to guide them to target tissues or cell types; leveraging oligonucleotide packing for amplified dosing, whichMore enables specific RNA molecules to be preferentially loaded into exosomes as a therapeutic cargo; ligand-based exosome affinity purification that isolates and purifies exosomes from biofluids like blood and cell culture media. Its engineered EVs products comprise Fortrexo CoV for the treatment of SARS-CoV-2 infection; Cognevo for the treatment of neuro degeneration; and PlexoDox for the treatment of cancer. Exopharm Limited has a research collaboration with Showa Denko Materials Co., Ltd. The company was incorporated in 2013 and is based in Melbourne, Australia.
4.8 / 5.0 (50)

Exopharm Limited reports have an aggregate usefulness score of 4.8 based on 50 reviews.

Exopharm Limited

Most Recent Annual Report

Exopharm Limited
MOST RECENT 2022 Annual Report

Older/Archived Annual Reports

Exopharm Limited Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!